Premium
Evaluation of an ankylosing spondylitis education and self‐management program: Beneficial effects on ankylosing spondylitis specific outcomes
Author(s) -
Inderjeeth Charles A.,
Boland Emma,
Connor Clara,
Johnson Christina,
Jacques Angela,
McQuade Jean
Publication year - 2021
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.14070
Subject(s) - ankylosing spondylitis , medicine , quality of life (healthcare) , physical therapy , interquartile range , spondylitis , anxiety , depression (economics) , nursing , psychiatry , macroeconomics , economics
Background Self‐management programs have demonstrated significant health benefits in people with musculoskeletal diseases. Aim To examine the benefits of a tailored ankylosing spondylitis self‐management program (ASSMP) delivered by trained health professionals for people with ankylosing spondylitis (AS) relative to health status, quality of life and disease activity. Methods ASSMP was developed within a continuous quality improvement framework following a needs assessment and focus group discussions. Formal feedback from the group after each 6 week program cycle group by questionnaire helped refine the ASSMP. Patient health status, quality of life and disease activity were assessed at multiple time points up to 12 months. Results Fifty‐five percent were female; mean age 48.5 ± 15.2 years. Median time to AS diagnosis was 4 years (interquartile range: 1‐10). AS disease activity Bath Ankylosing Spondylitis Global Score scores improved at 3, 6 and 12 months ( P < .001). Bath Ankylosing Spondylitis Disease Activity Index improved at 6 weeks and was sustained at 3, 6 and 12 months ( P < .001). The Ankylosing Spondylitis Quality of Life improved at 3, 6 and 12 months ( P < .001). Bath Ankylosing Spondylitis Functional Index improved by 12 months ( P < .001). Participants reported less nocturnal back pain at 6 months and was sustained at 12 months ( P < .001). Patients Global Disease Activity improved by 6 months ( P = .012), Multi‐Dimensional Assessment of Fatigue and a Global Fatigue Index at 6 months ( P = .003), Hospital Anxiety and Depression Scale ‐ Anxiety at 12 months ( P = .001), Evaluation Ankylosing Spondylitis Quality of Life at 6 months ( P = .001) and Pain Self‐Efficacy Questionnaire at 12 months ( P = .002). Conclusion This ASSMP demonstrated significant and sustained benefit in symptoms, disease activity measures and quality of life in a condition that results in significant impairment, disability and poorer quality of life. The cost effectiveness and benefit of this program should be tested.